The OSUCCC Clinical Trials Office (CTO), rated """"""""Excellent to Outstanding"""""""" in the 1999 review, supports the centralized administration of protocol conduct, development, review, implementation, monitoring, regulatory compliance, and quality assurance. The CTO is a shared resource of the OSUCCC that provides centralized management of all clinical trials conducted within the OSUCCC. The mission of the CTO is to foster a supportive environment conducive to the conduct of clinical trials by OSUCCC members and to provide a centralized resource to OSUCCC investigators for protocol administration, tracking and monitoring, data management, regulatory guidance, and financial management necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO came under the medical leadership o! John Byrd, M.D., and administrative leadership of Susan Ebert, R.D., M.S., in 2001. Since that time, the clinical research staff of Radiation Oncology, Stem Cell Transplant Program, Head & Neck Oncology, The Cancer and Leukemia Group B (CALGB), The AIDS-Related Malignancy Consortium (AMC), The CLL Research Consortium, and The NCI/CTEP Phase I Program have been consolidated within the CTO. This effort of consolidation as well as new clinical research faculty recruits and a consequent 232% increase in accrual to investigator-initiated studies (580 in 1999 and 1,926 in 2003) has resulted in the current CTO staffing of 38.5 FTE for its 224 open protocols, including 12 funded through NCI R21 QuickTrial grants. With recent acquisition of 7,000 nsf of space for the CTO, plans are to consolidate 20 remaining research staff conducting select cooperative group trials (ACOSOG, NSABP, and GOG) over the next two years in order to finalize centralization of all cancer clinical research activities. The CTO has reinforced infrastructure in the past several years with the creation of two new position titles, Regulatory Coordinator and Financial Manager. In addition, management infrastructure was improved with the creation of two new supervisory roles, the Clinical Research Manager (who manages all research nurses) and Data Management Supervisor (who manages research associates). A new web-based Cancer Research Information System (CRIS) has been developed for use by the CTO staff that vastly improves tracking of all research activities and provides the OSUCCC leadership and membership with the tools to monitor progress; 2627 patients were entered on trials and registered into the CTO CRIS database during the most recent 12-month period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630226
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$334,851
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications